Warts are common in renal allograft recipients, with a reported incidence of warts ranging from 24% to 100%. These patients also demonstrate an accelerated course from wart to carcinoma. Although the histologic appearance of common warts is predictable in immunocompetent patients, this has not been shown in renal allograft recipients. The purpose of the study was to evaluate the histopathologic findings of warty lesions in renal allograft recipients and to determine the degree of dysplasia or malignant transformation in such lesions. We examined 55 renal allograft recipients for warty lesions. We obtained biopsy specimens from 50 lesions that appeared on clinical examination to be common warts and evaluated their histopathologic features. Median time from transplantation was 49 months (<5 years). All patients were treated with cyclosporine, azathioprine, and prednisolone. Among 55 renal allograft recipients, 17 patients (30.9%) had warty lesions. Forty-seven lesions (94%) showed changes of verruca vulgaris on histologic examination, and only three lesions (6%) showed warts with mild dysplasia. No malignant transformation was reported. Our findings were in contrast to a previous, similar study. This may be attributable to the relatively short period from transplantation to biopsy in our patients.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
customersupport@researchsolutions.com
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.